Abstract/full free access: Symptom Interpretation and Health Care Seeking In Ovarian Cancer

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

(abstract) Conclusions

Diagnostic delay in ovarian cancer seems far from being exclusively a medical problem, as the delay proved to be influenced by organisational, cultural, and social factors, too. Initiatives facilitating the diagnostic process and research concerning the selection of individuals for further investigation are indicated. The way in which the women interpreted their symptoms was influenced by their personal experiences, their cultural, and their social background. This became crucial to the diagnostic process. These issues need to be explored through further research on women's experiences during the diagnostic process.

June 3rd: Personalized Therapy Benefits Late-Stage Cancer Patients in Clinical Trial - Cancerwise | Cancer blog from MD Anderson Cancer Center

"Researchers analyzed tumors of 1,144 patients with metastatic or inoperable cancer. Their median age was 58, and the median number of prior treatments was four. Of these, 460 had one or more gene defects targetable by available approved or experimental drugs."

Cancer-Related Fatigue: Integrative Therapies Can Help - Cancerwise | Cancer blog from MD Anderson Cancer Center

Cancerwise newsletter: Patients Face Debilitating Challenges Related to Toxicities in Cancer Treatment

recruiting: Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma - Full Text View - ClinicalTrials.gov

abstract- Gynecologic Oncology : Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer

Research highlights

► Three variants in CASP8 gene decreased risk of epithelial ovarian cancer (EOC).
► A reduced risk of EOC was significantly associated with the del-C-T haplotype of those 3 SNPs.
► A notable later age at onset of EOC was associated with rs3834129 of CASP8 gene.

HRT Post Oophorectomy Adds No Breast Cancer Risk : Internal Medicine News

"....The PROSE database was developed by 20 centers in the United States and Europe who identified and prospectively followed women with a deleterious BRCA1 or BRCA2 mutation. For the study, the investigators focused on those who at ascertainment had at least one ovary, no prior breast or ovarian cancer, no prior bilateral mastectomy, and at least 6 months of follow-up. ...."

abstract: Effect of Misclassified Underlying Cause of Death on Survival Estimates of Colon and Rectal Cancer

abstract- Gynecologic Oncology : Comparison of candidate serologic markers for type I and type II ovarian cancer

Objective

To examine the value of individual and combinations of ovarian cancer associated blood biomarkers for the discrimination between plasma of patients with type I or II ovarian cancer and disease-free volunteers.

Research highlights

► We compared 14 biomarkers to discriminate the plasma samples of healthy volunteers and ovarian cancer patients.
► Autoantibodies to p53 and NY-ESO-1 were present in plasma of type II but not type I ovarian cancer patients.
► Combining p53 AAbs with CA125 significantly improved discrimination of plasma of type II cancer patients from that of healthy volunteers.
 

ongoing: Research Study in Patients With Advanced Epithelial Ovarian Cancer - Full Text View - ClinicalTrials.gov

Purpose

RATIONALE: Analyzing tissue samples from patients in the laboratory may help doctors learn more about cancer.

PURPOSE: The purpose of this study is to analyze tissue samples from patients with ovarian cancer in the laboratory.

Condition	Intervention
Ovarian Cancer	Genetic: comparative genomic hybridization Genetic: cytogenetic analysis Genetic: gene rearrangement analysis Genetic: microarray analysis Genetic: mutation analysis Genetic: polymerase chain reaction

UK: Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer - Full Text View - ClinicalTrials.gov

phase 11 - Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma - Full Text View - ClinicalTrials.gov (not yet recruiting)

Biological: Chimeric monoclonal antibody (TRC105) to CD105

10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle

Other Names:

• TRC105
• NSC#754227

media: (PARP inhibitors) Researchers: Breast Cancer Drug May Treat Other Cancers

Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients (rs1649942)

abstract: Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer

No associations were found between glucose levels and ovarian cancer risk.

press release: Ovarian Cancer National Alliance Urges FDA Not to Limit Access to Avastin (Bevacizumab) for Women with Ovarian Cancer | Ovarian Cancer National Alliance

Abstract/full free access: BRCA in the Ashkenazi Population: Are Current Testing Guidelines Too Exclusive?

(The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production) 

Abstract:

 The BRCA1/2 genes account for a significant portion of hereditary breast and ovarian cancers and they are especially prevalent in the Ashkenazi Jewish population. Women who have a mutation can prevent breast and ovarian cancer with surgical intervention. We describe an Ashkenazi Jewish patient who illustrates that current testing criteria are too restrictive, particularly for this population of patients. The patient's sister was diagnosed with breast cancer at age 33; however, she was not a mutation carrier. Based on practice guidelines, the patient was not recommended genetic testing. She subsequently underwent direct-to-consumer (DTC) testing and discovered that she was a mutation carrier. This case demonstrates the need for clinicians to be aware of the higher prevalence of BRCA mutations in the Ashkenazi population. It also exemplifies the need to involve medical professionals, including genetic counselors, in the dissemination of DNA test results.

Chemo Drug (Taxol) Shortage Leaves Doctors Scrambling and Cancer Patients at Risk, Highlighting Increasingly Unreliable Drug Supplies - ABC News

CMAJ: Can rationing possibly be rational? (the case of Annie Farlow/ethics discussions))

Author Insights: Some Clinical Trials Intended for Drug Marketing, Not Advancing Science « news@JAMA (seeding trials)

summary: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer : The Lancet Oncology

Cancer survivors: still room for improvement : The Lancet Oncology

NBOCC News - June 2011 - National Breast and Ovarian Cancer Centre (NBOCC)

In this issue...

• A reflection on National Breast and Ovarian Cancer Centre's achievement
• Cancer Australia and National Breast and Ovarian Cancer Centre amalgamate
• Not just a woman's disease: Information about breast cancer in men
• New clinical practice guidelines on use of bisphosphonates in advanced breast cancer
• GP online learning on cancer screening
• Understanding ductal carcinoma in situ resource
• New Clinical Update: Ovarian Cancer

Australia - Ovarian Cancer - issue 13 - National Breast and Ovarian Cancer Centre (NBOCC) Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity